Share This Page
Suppliers and packagers for generic pharmaceutical drug: SELEGILINE
✉ Email this page to a colleague
SELEGILINE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Somerset | EMSAM | selegiline | FILM, EXTENDED RELEASE;TRANSDERMAL | 021336 | NDA | Viatris Specialty LLC | 49502-900-05 | 5 POUCH in 1 CARTON (49502-900-05) / 1 PATCH in 1 POUCH (49502-900-11) / 24 h in 1 PATCH | 2006-02-27 |
| Somerset | EMSAM | selegiline | FILM, EXTENDED RELEASE;TRANSDERMAL | 021336 | NDA | Viatris Specialty LLC | 49502-900-30 | 30 POUCH in 1 CARTON (49502-900-30) / 1 PATCH in 1 POUCH (49502-900-01) / 24 h in 1 PATCH | 2006-02-27 |
| Somerset | EMSAM | selegiline | FILM, EXTENDED RELEASE;TRANSDERMAL | 021336 | NDA | Viatris Specialty LLC | 49502-901-30 | 30 POUCH in 1 CARTON (49502-901-30) / 1 PATCH in 1 POUCH (49502-901-01) / 24 h in 1 PATCH | 2006-02-27 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Selegiline
Introduction
Selegiline, also known as L-deprenyl, is a selective monoamine oxidase B (MAO-B) inhibitor primarily employed in the treatment of Parkinson's disease and major depressive disorder. Its unique pharmacological profile and therapeutic efficacy make selegiline a sought-after compound. The global supply chain involves a complex interplay of active pharmaceutical ingredient (API) manufacturers, formulators, and distributors. This article examines the leading suppliers of selegiline, detailing their production capacities, geographical footprints, regulatory compliance, and strategic influence in the pharmaceutical market.
Market Overview
The demand for selegiline has steadily increased, driven by aging populations and expanded indications beyond Parkinson's disease, including cognitive decline and mood disorders. The supply chain's robustness hinges on APIs’ quality, regulatory adherence, and manufacturing scale. Key suppliers operate across regions including India, China, Europe, and North America, leveraging specialized expertise and manufacturing infrastructure.
Major Active Pharmaceutical Ingredient (API) Manufacturers of Selegiline
1. Zhejiang Yuejun Pharmaceutical Co., Ltd.
Based in China, Zhejiang Yuejun Pharmaceutical is one of the prominent API producers of selegiline. With extensive capabilities in synthesizing MAO-B inhibitors, the company adheres to international quality standards, including ISO and GMP certifications. Its production capacity caters to both domestic and international pharmaceutical companies, supplying bulk API for formulations.
2. Mallinckrodt Pharmaceuticals
Mallinckrodt, headquartered in Ireland, is a global pharmaceutical company with a broad portfolio, including APIs such as selegiline. While primarily focused on branded medications, Mallinckrodt also supplies high-grade APIs to generic manufacturers globally, leveraging advanced manufacturing processes and rigorous quality controls.
3. Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui, a leading Chinese pharmaceutical firm, has diversified into active ingredients, including selegiline. Its manufacturing facilities comply with stringent GMP standards, and it has substantial export volume, especially to North American and European markets.
4. Sun Pharmaceutical Industries Ltd.
An Indian multinational, Sun Pharma produces a wide range of APIs, including selegiline. The company’s API division emphasizes quality and cost competitiveness, driven by state-of-the-art manufacturing plants in India and licensed facilities complying with global standards.
5. Zhanjiang Guolan Pharmaceutical Co., Ltd.
This Chinese manufacturer supplies selegiline API with an emphasis on competitive pricing and high-volume production. It maintains certifications from European and US regulators, positioning itself as a reliable supplier for generic medication producers.
Formulation and Finished Dose Suppliers
While API production is vital, formulation companies that incorporate selegiline into finished dosage forms are equally impactful in the supply chain.
6. Teva Pharmaceutical Industries
Teva, one of the world's largest generics companies, sources selegiline APIs and manufactures tablets in various formulations. The company’s extensive distribution network ensures global reach, especially across developed markets.
7. Grünenthal GmbH
This German pharmaceutical firm develops high-quality formulations of selegiline, notably for transdermal patches and oral tablets. Their adherence to European regulatory standards ensures compliance and supply stability.
8. Hikma Pharmaceuticals
Hikma, headquartered in Jordan, markets generic selegiline formulations across multiple regions. Its strategic sourcing involves partnerships with API manufacturers like those in China and India.
Regional Dynamics and Regulatory Considerations
Asia (China & India)
China and India dominate the API production landscape for selegiline, accounting for over 70% of global API manufacturing capacity. Chinese companies benefit from governmental support and large-scale manufacturing facilities, while Indian firms leverage cost advantages and mature regulatory frameworks. However, regulatory oversight varies, with some manufacturers facing scrutiny over GMP compliance, prompting buyers to conduct thorough audits.
Europe & North America
European and American manufacturers often focus on high-quality APIs with strict adherence to GMP standards, benefiting from regulatory agencies such as the EMA and FDA. These firms cater to premium markets, emphasizing rigorous quality control, and are often involved in innovative formulations and delivery systems.
Regulatory Challenges
Suppliers must navigate complex regulatory environments, including API registration, good manufacturing practices, and environmental compliance. Recent initiatives to tighten regulatory oversight in China and India aim to improve API quality and traceability, impacting supply chain stability and timelines.
Supply Chain Challenges and Strategic Implications
The supply of selegiline faces challenges including quality assurance, geopolitical risks, and raw material availability. The COVID-19 pandemic exposed vulnerabilities, prompting pharmaceutical companies to diversify suppliers and establish strategic inventories. Importantly, the consolidation of API manufacturers and increased regulatory scrutiny have impacted pricing and lead times.
Strategic considerations for pharmaceutical companies:
- Supplier diversification: Engaging multiple suppliers across regions to mitigate risks.
- Quality assurance: Prioritizing suppliers with robust GMP certifications and transparent sourcing.
- Regulatory compliance: Ensuring API sources meet international standards to avoid approval delays.
- Cost management: Balancing quality with cost advantages from Asian manufacturers.
Emerging Trends and Future Outlook
The future of selegiline supply hinges on developments in manufacturing technology, regulatory harmonization, and market expansion. Innovations such as continuous manufacturing and advanced analytical techniques aim to enhance API quality and supply stability. Additionally, patent expirations and the rise of generic formulations are expected to increase demand for reliable API suppliers.
Companies investing in quality improvements and supply chain resilience will likely gain competitive advantages. Moreover, increasing collaborations between Western pharmaceutical firms and Asian API manufacturers signal a trend toward integrated supply chain models. As global demand rises, capacity expansion and regulatory compliance will remain critical determinants of supplier viability.
Key Takeaways
- The global supply chain for selegiline is heavily centered in China and India, with European and North American firms emphasizing high-quality standards.
- Leading API suppliers include Zhejiang Yuejun Pharmaceutical, Jiangsu Hengrui, Sun Pharma, and Zhanjiang Guolan.
- Strategic supplier diversification and rigorous quality assurance are vital for mitigating supply risks.
- Regulatory compliance and GMP certification influence supplier credibility and market access.
- Innovations in manufacturing and increased regulatory harmonization will shape the future landscape of selegiline supply.
Frequently Asked Questions
1. Who are the leading global suppliers of selegiline API?
Major suppliers include Chinese companies like Zhejiang Yuejun Pharmaceutical and Zhanjiang Guolan, Indian firms such as Sun Pharma, and multinational corporations like Mallinckrodt and Jiangsu Hengrui.
2. What factors should pharmaceutical companies consider when sourcing selegiline API?
Quality standards (GMP compliance), manufacturing capacity, cost, regulatory approval, supplier reputation, and supply chain stability are critical considerations.
3. How has the COVID-19 pandemic impacted selegiline supply chains?
Disruptions in manufacturing, transportation delays, and raw material shortages prompted companies to diversify suppliers and build strategic inventories to ensure supply continuity.
4. What are regulatory challenges associated with selegiline API?
Ensuring compliance with GMP standards, obtaining API registration approvals in key markets, and maintaining traceability are significant challenges facing suppliers.
5. What innovations are emerging to enhance the supply of selegiline?
Technologies such as continuous manufacturing, real-time analytical monitoring, and digital quality control are improving API consistency, reducing lead times, and increasing transparency.
References
[1] European Medicines Agency. "Selegiline: Product information." EMA, 2022.
[2] U.S. Food and Drug Administration. "API Registration and Regulatory Framework." FDA, 2022.
[3] PharmaIQ. "Global API Manufacturing Landscape." PharmaIQ, 2021.
[4] IQVIA Institute. "The Future of Active Pharmaceutical Ingredient Supply Chains." IQVIA, 2023.
[5] MarketWatch. "Selegiline Market Analysis and Trends." MarketWatch, 2022.
More… ↓
